We are live on ! Find out more
EUCR

Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR

Delisted

EUCR was delisted on the 26th of April, 2023.

Back to rankings

38 hedge funds and large institutions have $84.5M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

11% more capital invested

Capital invested by funds: $76.1M → $84.5M (+$8.48M)

3% more funds holding

Funds holding: 37 → 38 (+1)

Holders
38
Holders Change
+1
Holders Change %
+2.7%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$6.94M
2
MF
Magnetar Financial
Illinois
+$3.73M
3
MC
Meteora Capital
Florida
+$559K
4
FTCM
First Trust Capital Management
Illinois
+$386K
5
MSU
Mizuho Securities USA
New York
+$191K

Top Sellers

Rank Fund Capital Flow
1
ECU
Eisler Capital (UK)
United Kingdom
-$3.07M
2
SCM
Suvretta Capital Management
New York
-$990K
3
BCM
Basso Capital Management
Connecticut
-$430K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$365K
5
Goldman Sachs
Goldman Sachs
New York
-$249K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
$10.2M +$6.94M +696,605 +214%
DM
2
Deerfield Management
New York
$10M – – –
BlackRock
3
BlackRock
New York
$9.02M -$3.08K -309 -0%
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
$6.68M – – –
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$6.53M -$365K -36,608 -5%
6CM
6
683 Capital Management
New York
$6.01M – – –
MF
7
Magnetar Financial
Illinois
$4.38M +$3.73M +374,296 +597%
ACM
8
Altium Capital Management
New York
$4.01M – – –
CH
9
CVI Holdings
Delaware
$3.69M – – –
SCM
10
Saba Capital Management
New York
$2.71M – – –
FTCM
11
First Trust Capital Management
Illinois
$2.09M +$386K +38,740 +23%
EC
12
EcoR1 Capital
California
$2M – – –
KCM
13
Kingdon Capital Management
New York
$2M – – –
PC
14
Periscope Capital
Ontario, Canada
$1.79M +$13.9K +1,400 +0.8%
PAMP
15
Polar Asset Management Partners
Ontario, Canada
$1.6M – – –
SC
16
Sculptor Capital
New York
$1.56M – – –
CC
17
Centiva Capital
New York
$1.41M – – –
WRBC
18
W.R. Berkley Corp
Connecticut
$1.19M – – –
Jane Street
19
Jane Street
New York
$1.09M +$23.8K +2,386 +2%
RCM
20
Radcliffe Capital Management
Pennsylvania
$1.03M – – –
RCM
21
Rivernorth Capital Management
Florida
$1M – – –
Millennium Management
22
Millennium Management
New York
$802K -$25.5K -2,556 -3%
CF
23
Cantor Fitzgerald
New York
$741K – – –
SIA
24
SkyView Investment Advisors
New Jersey
$719K – – –
MC
25
Meteora Capital
Florida
$562K +$559K +56,076 New
1
2

EUCR Hedge Fund Activity: Q3 2022 in Review

38 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q3 2022, worth a combined $84.5M — up 11% from $76.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EUCR positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $6.94M. The largest seller was Eisler Capital (UK), exiting entirely with an estimated $3.07M sold.

  • 38 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q3 2022, up from 37 in Q2 2022.
  • Funds reported $84.5M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q3 2022, up 11% quarter-over-quarter.
  • 5 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q3 2022 and 4 closed out, a net change of +1 holder.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q3 2022 was Glazer Capital LLC, an estimated $6.94M added.
  • The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q3 2022 was Eisler Capital (UK), an estimated $3.07M sold.

Based on aggregated 13F filings for Q3 2022.